Adaptive Biotechnologies Corp- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Adaptive Biotechnologies Corp 公司

Adaptive Biotechnologies Corporation 是一家商业阶段的生物技术公司。该公司专注于利用适应性免疫系统的固有生物学来改变疾病的诊断和治疗。其免疫医学平台应用其专有技术来读取患者免疫系统的多种遗传密码，并准确了解免疫系统如何检测和治疗该患者的疾病。该公司的业务主要围绕两个领域：淋巴恶性肿瘤中微小残留病 (MRD) 的临床评估和免疫医学 (IM) 驱动的药物发现和开发。MRD 业务专注于使用其高灵敏度的下一代测序 (NGS) 检测来测量血液系统恶性肿瘤患者的 MRD。该公司包括向临床医生提供的 clonoSEQ 临床诊断测试和向生物制药合作伙伴提供的 clonoSEQ 检测，以推进药物开发工作 (MRD Pharma)。

公司简介

公司代码ADPT

公司名称Adaptive Biotechnologies Corp

上市日期Jun 27, 2019

成立日期2009

CEOMr. Chad M. Robins

员工数量619

证券类型Ordinary Share

年结日Jun 27

公司地址1165 Eastlake Ave E

城市SEATTLE

上市交易所NASDAQ Global Select Consolidated

国家United States of America

邮编98109

电话12066590067

网址https://www.adaptivebiotech.com

公司代码ADPT

上市日期Jun 27, 2019

成立日期2009

公司高管

名称

名称/职务

职务

持股

持股变动

Mr. Chad M. Robins

Chairman of the Board, Chief Executive Officer, Co-Founder

2.10M

-4.49%

Ms. Susan Bobulsky

Chief Commercial Officer - MRD

347.24K

+37.09%

Mr. Francis Lo

Chief People Officer

332.85K

+31.17%

Mr. Peter M. Neupert

Lead Independent Director

209.30K

+8.24%

Dr. Sharon Benzeno, Ph.D.

Chief Commercial Officer - Immune Medicine

95.93K

-15.18%

Dr. Katey Einterz Owen, Ph.D.

Independent Director

57.23K

+42.41%

Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.

Independent Director

54.30K

+41.54%

Mr. Kyle Piskel

Chief Financial Officer

47.39K

-3.91%

Ms. Karina Calzadilla

Vice President - Investor Relations

--

Ms. Julie Rubinstein

President, Chief Operating Officer

--

名称

名称/职务

职务

持股

持股变动

Mr. Chad M. Robins

Chairman of the Board, Chief Executive Officer, Co-Founder

2.10M

-4.49%

Ms. Susan Bobulsky

Chief Commercial Officer - MRD

347.24K

+37.09%

Mr. Francis Lo

Chief People Officer

332.85K

+31.17%

Mr. Peter M. Neupert

Lead Independent Director

209.30K

+8.24%

Dr. Sharon Benzeno, Ph.D.

Chief Commercial Officer - Immune Medicine

95.93K

-15.18%

Dr. Katey Einterz Owen, Ph.D.

Independent Director

57.23K

+42.41%

收入明细

单位: USD更新时间: 4月6日周日

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

业务USD

名称

营收

占比

MRD revenue

145.53M

81.32%

Immune meidicine revenue

33.43M

18.68%

暂无数据

业务

地区

业务USD

名称

营收

占比

MRD revenue

145.53M

81.32%

Immune meidicine revenue

33.43M

18.68%

股东统计

更新时间: 6月11日周三

持股股东

股东类型

持股股东

占比

Viking Global Investors LP

19.74%

Rubric Capital Management LP

8.63%

The Vanguard Group, Inc.

7.32%

BlackRock Institutional Trust Company, N.A.

6.45%

Columbia Threadneedle Investments (US)

4.27%

Other

53.59%

持股股东

占比

Viking Global Investors LP

19.74%

Rubric Capital Management LP

8.63%

The Vanguard Group, Inc.

7.32%

BlackRock Institutional Trust Company, N.A.

6.45%

Columbia Threadneedle Investments (US)

4.27%

Other

53.59%

股东类型

持股股东

占比

Investment Advisor/Hedge Fund

53.09%

Investment Advisor

23.82%

Hedge Fund

17.68%

Individual Investor

2.66%

Research Firm

2.15%

Private Equity

0.68%

Venture Capital

0.40%

Bank and Trust

0.30%

Pension Fund

0.28%

机构持股

更新时间: 2月22日周六

报告期

机构数

持股数

持股占比

持股变动

2025Q1

476

143.19M

94.26%

-9.97M

2024Q4

481

143.31M

96.47%

-18.10M

2024Q3

478

143.38M

97.20%

-27.99M

2024Q2

486

149.83M

101.63%

-16.40M

2024Q1

506

146.67M

99.58%

-10.66M

2023Q4

529

145.23M

100.12%

-16.05M

2023Q3

531

142.64M

98.54%

-11.65M

2023Q2

545

137.84M

95.31%

-15.76M

2023Q1

577

135.96M

94.24%

-11.97M

2022Q4

616

132.93M

92.90%

-17.07M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

Viking Global Investors LP

29.99M

20.19%

--

Dec 31, 2024

Rubric Capital Management LP

14.60M

9.83%

+200.00K

+1.39%

Dec 31, 2024

The Vanguard Group, Inc.

10.69M

7.19%

+47.48K

+0.45%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

9.81M

6.6%

+55.67K

+0.57%

Dec 31, 2024

Nikko Asset Management Co., Ltd.

6.83M

4.6%

-900.75K

-11.65%

Dec 31, 2024

ARK Investment Management LLC

9.42M

6.34%

-2.18M

-18.77%

Dec 31, 2024

Millennium Management LLC

6.29M

4.24%

-3.11M

-33.06%

Dec 31, 2024

Aristotle Atlantic Partners, LLC

2.89M

1.94%

-114.50K

-3.82%

Dec 31, 2024

持股ETF

更新时间: 6月6日周五

机构名称

占比

ARK Genomic Revolution ETF

4.33%

ROBO Global Healthcare Technology & Innovation ETF

1.82%

Franklin Genomic Advancements ETF

1.53%

First Trust Small Cap Growth AlphaDEX Fund

0.84%

Invesco NASDAQ Future Gen 200 ETF

0.7%

First Trust Nasdaq Lux Digi Health Solutions ETF

0.49%

Invesco Dorsey Wright SmallCap Momentum ETF

0.49%

First Trust Small Cap Core Alphadex Fund

0.41%

iShares Micro-Cap ETF

0.2%

Invesco Nasdaq Biotechnology ETF

0.14%

ARK Genomic Revolution ETF

占比4.33%

ROBO Global Healthcare Technology & Innovation ETF

占比1.82%

Franklin Genomic Advancements ETF

占比1.53%

First Trust Small Cap Growth AlphaDEX Fund

占比0.84%

Invesco NASDAQ Future Gen 200 ETF

占比0.7%

First Trust Nasdaq Lux Digi Health Solutions ETF

占比0.49%

Invesco Dorsey Wright SmallCap Momentum ETF

占比0.49%

First Trust Small Cap Core Alphadex Fund

占比0.41%

iShares Micro-Cap ETF

占比0.2%

Invesco Nasdaq Biotechnology ETF

占比0.14%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

Adaptive Biotechnologies Corp

12.300USD

Adaptive Biotechnologies Corp

12.300

概览

公司